Lead Product(s): OBI-999
Therapeutic Area: Oncology
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 21, 2020
Second Orphan Drug Designation for OBI-999, Antibody-Drug Conjugate in combination with a validated payload (MMAE) & the antibody targeting Globo H, a glycolipid antigen found on multiple tumor types.